Amryt Pharma PLC Fundamentals Datasheet and Stock Analysis

Profile

Amryt Pharma PLC Company Logo
Amryt Pharma plc is a commercial-stage specialty pharmaceutical company focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company’s lead products include AP 101 and AP102. AP101 (Episalvan) is a potential treatment for Epidermolysis Bullosa (EB), and it is in Phase III clinical trials. AP102 is focused on developing novel, next generation somatostatin analogue (SSA) peptide medicines for patients with rare neuroendocrine diseases. The Company holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union (EU) and other territories, including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body’s ability to remove LDL cholesterol (bad cholesterol) from the blood.

  • Current Price:
     199.00p
  • Industry:
     Health Care
  • Sector:
     Health Care
  • ISIN:
     GB00BDD1LS57
  • Market Sector:
     AIM
  • Main Indices:
     FTSE AIM
  • Country of register:
     Great Britain
  • Currency:
     N/A
  • Shares in Issue:
     163m
  • Market Cap:
     £333m
  • Date Listed:
     19/04/2016
Operation Breakdown
Geographical - by origin (turnover)
Product (turnover)

Loading...

Activity Data Not Available

Company Information

CEO: Joe Wiley  CFO: Rory Nealon  Non-Executive Director: George Hampton, Stephen Wills, Alain Munoz, Donald Stern Patrick Vink  Non-Executive Chairman: Ray Stafford  

Analysis
Composite Ranking: 35
Historic EPS Ranking: 38
Forecast EPS Ranking: 39
Price Relative Strength: 
Industry Strength: I
SMR Ranking: E
ROCE Ranking: B
Accumulation/Dist: 
Mkt Accumulation/Dist: C
Unbroken Annual EPS: E
Unbroken Interim EPS: E
PEG Current Ranking: A
PEG Forecast Ranking: A
PE Current Ranking: A
PE Forecast Ranking: A
Margin Current Ranking: H
Margin Forecast Ranking: D
Chart
Add Indicator




loading




Takes the average of data over a period of time, and migrates the period across the data series one data point at a time. This formula smooths a data series and makes analysing volatile data easier.
Fundamentals
20142015201520162017201820192020E2021E
Day/Month31/331/1231/331/1231/1231/1231/1231/1231/12
Revenue$m0.000.000.001.3512.7817.0958.12€m132.66171.85
Operating Profit/(loss)$m(2.93)(0.55)(2.04)(7.68)(14.21)(18.04)(53.75)€m0.000.00
Profit Before Tax$m(2.56)(1.19)(1.87)(7.80)(26.14)(30.44)(66.76)€m(58.10)(13.79)
Profit After Tax$m(2.56)(1.19)(1.87)(7.80)(26.14)(30.49)(65.54)€m0.000.00
Profit After Tax (from discontinued operations)$m0.000.00(34.10)0.000.000.000.00€m0.000.00
Overall Profit for the Period$m(2.56)(1.19)(35.97)(7.80)(26.14)(30.49)(65.54)€m0.000.00
EPS Growth%0.000.000.000.000.000.000.00%0.000.00
Earnings Per Share¢(0.87)(12.84)(34.40)(28.68)(70.32)(402.00)(86.00)p(19.94)(1.15)
Op. Cash Flow P/S¢(0.34)(1.63)(0.52)(0.24)(0.38)(0.34)(0.49)0.000.00
Cash Flow P/S Grth%0.000.000.000.000.000.000.00%0.000.00
Net Cash Flow P/S¢0.000.000.000.000.000.000.000.000.00
Capital Exp P/S$0.000.000.000.000.000.000.000.000.00
Tax Rate%0.000.000.000.000.000.000.00%0.000.00
P/E Ratiox0.000.000.000.000.000.000.00x0.0024.70
P/E Growth$0.000.000.000.000.000.000.000.000.00
Turnover Per Share$0.000.000.000.000.000.000.000.000.00
Pre-Tax Profit / Share$0.000.000.000.000.000.000.000.000.00
Operating Margin%0.000.000.00(568.89)(111.19)(105.51)(92.48)%0.000.00
ROCE%(5.24)(11.98)(13.71)(12.64)(35.98)(41.93)(13.42)%0.000.00
ROE%(5.18)(76.30)(108.07)(33.94)(102.80)(270.28)(104.33)%0.000.00
Mkt Cap$m29.2025.8720.08190.39196.49171.84196.90€m0.000.00
Dividend Per Share¢0.000.000.000.000.000.000.00p0.000.00
DPS Growth%0.000.000.000.000.000.000.00%0.000.00
Dividend Yield%0.000.000.000.000.000.000.00%0.000.00
Dividend Coverx0.000.000.000.000.000.000.00x0.000.00
Shareholder Funds$m55.94(1.19)14.9033.0421.89(3.70)129.32€m0.000.00
Net Borrowings$m(17.43)(0.17)(15.20)(8.27)(20.51)(11.23)(67.23)€m0.000.00
Net Assets$m55.94(1.19)14.9033.0421.89(3.70)129.32€m0.000.00
Net Assets P/S$0.000.000.000.000.000.000.000.000.00
Financials
Latest Forecast
Div Yield0.0%0.0%
Div Cover0.0%0.0%
Op Margin-92.5%-43.8%
ROCE123.8%
Director Deals
Traded Action Notifier Price Amount Value
20-May-20BuyRay Stafford110.00p50,000,355,000
07-Jan-20BuyJoe Wiley121.90p7,999,639,750.78
30-Aug-19PlacingRay Stafford90.00p918,273£,826,445.68
09-Oct-17PlacingJames Culverwell20.00p221,592,344,318.40
09-Oct-17PlacingRory Nealon20.00p221,592,344,318.40
09-Oct-17PlacingJoe Wiley20.00p221,592,344,318.40
09-Oct-17PlacingHarry Stratford20.00p150,000,330,000
09-Oct-17PlacingMarkus Ziener20.00p132,955,326,591
09-Oct-17PlacingJoe Wiley20.00p 221,592£44,318.40
09-Oct-17PlacingRory Nealon20.00p 221,592£44,318.40
First PagePrev PageNext Page  Rows per page
Shareholders
163m    Major: 51%    Director: 4%
Notifier Holding Value
Joe Wiley3,507,080,979,089.20
Rory Nealon1,610,771,205,434.29
Ray Stafford1,363,501,713,366.99
  Rows per page
Gearing & Cover
News
News Title Date Time Source
Q1 2020 RESULTS11-May-2007:00RNS
FY 2019 RESULTS11-May-2007:00RNS
Notice of Results07-May-2009:00RNS
FILSUVEZ CONFIRMED AS GLOBAL BRAND NAME FOR AP10107-May-2007:00RNS
EASE CLINICAL STUDY UPDATE23-Apr-2007:00RNS
Holding(s) in Company25-Mar-2007:00RNS
Market Update23-Mar-2007:00RNS
Draft registration statement for US Nasdaq listing19-Feb-2012:00RNS
Holding(s) in Company15-Jan-2017:16RNS
Amryt to present updates from its EB research15-Jan-2007:00RNS
First PagePrev PageNext Page  Rows per page
Broker Opinion
Date Broker Name Rec Price Old Price Target New Price Target Broker Change
18-May-20Berenberg BankHouse Stock106.00p0.00p0.00pReiteration
11-May-20Shore CapitalHold109.00p0.00p0.00pReiteration
  Rows per page
Notes

This functionality requires you to login

Click here to login
Or register for a new account